[en] Saliva may provide interesting advantages as matrix for compliance measurements, pharmacokinetic studies and therapeutic drug monitoring in resource limited countries. We investigated the feasibility of using saliva for compliance monitoring of zidovudine (ZDV), lamivudine (3TC) and nevirapine (NVP) in 29 HIV-1 infected patients from Rwanda. ZDV, 3TC and NVP drug levels were quantified by an LC/MS-MS method in plasma and stimulated saliva samples and compared using Bland-Altman analysis. Seven patients demonstrated undetectable saliva ZDV levels while five out of these seven also showed no 3TC salivary concentrations. For the other samples, we observed a good agreement between salivary and plasma concentrations of each antiretroviral drug. A significant relation between the difference in saliva and plasma ZDV concentrations and the average ZDV concentration in the two matrices was deduced as follow: y = -380.15 + 1.79 x. The log saliva and plasma concentration difference of both 3TC and NVP was consistent across the range of average log concentration. Overall, we showed large agreement limits suggesting a wide inter patient variability that may result to non-reliable plasma level predictions from saliva drug measurements. Therefore, our results indicate that saliva may serve as a valuable tool only for NVP compliance testing because of its high salivary concentration.
Disciplines :
Biotechnology
Author, co-author :
Gras, Alain
Schneider, Serge
Karasi, Jean Claude ; Université de Liège - ULiège > Doct. sc. bioméd. & pharma. (Bologne)
Ternes, Anne-Marie
Sauvageot, Nicolas
Karasi-Omes, Christine
Henry, Anne-Pascale
Schmit, Jean-Claude
Seguin-Devaux, Carole
Arendt, Vic
Language :
English
Title :
Evaluation of saliva as an alternative matrix for monitoring plasma Zidovudine, Lamivudine and nevirapine concentrations in Rwanda
Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med 2004; 42(11): 1273-1287.
Drummer OH. Drug testing in oral fluid. The Clin biochemist 2006; 27(3): 147-159.
Rolinski B, Wintergerst U, Matuschke A, et al. Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS 1991; 5(7): 885-888.
van Heeswijk RP, Veldkamp AI, Mulder JW, et al. Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. Ther Drug Monit 2001; 23(3): 255-258.
Hugen PW, Burger DM, de Graaff M, et al. Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir. Ther Drug Monit 2000; 22(4): 437-445.
Rakhmanina NY, Capparelli EV, van den Anker JN, et al. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit 2007; 29(1): 110-117.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476): 307-310.
Fischer A, Karasi JC, Kibibi D, et al. Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002. HIV Med 2006; 7(1): 64-66.
Karasi JC, Servais JY, Musonera F, et al. Immunovirological outcomes and drug resistance profiles of the Rwandese HIV ART Cohort. 7th European HIV Drug Resistance Workshop 25-27 March, 2009 Stockholm, Sweden Reviews in Antiviral Therapy. p. Abstract #24.
Lowrance DW, Ndamage F, Kayirangwa E, et al. Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr. 2009; 52(1): 49-55.
Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48(4): 450-454.
Lemmer P, Schneider S, Schuman M, et al. Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode. Ther Drug Monit. 2005; 27(4): 521-525.
Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995 21; 346(8982): 1085-1087.
Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999; 8(2): 135-160.
Rakhmanina NY, van den Anker JN, Soldin SJ. Therapeutic drug monitoring of antiretroviral therapy. Aids Patient Care STDS 2004; 18(1): 7-14.
Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45(9): 1230-1237.
Rendon A, Nunez M, Jimenez-Nacher I, Gonzalez de Requena D, Gonzalez-Lahoz J, Soriano V. Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med 2005; 6(5): 360-365.
Simoni JM, Frick PA, Lockhart D, Liebovitz D. Mediators of social support and antiretroviral adherence among an indigent population in New York City. Aids Patient Care STDS 2002; 16(9): 431-439.
Fraaij PL, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004; 26(2): 122-126.
Karasi JC, Musonera F, Servais JY, et al. HIV-1 molecular epidemiology and prevalence of drug resistance in treatment -naïve and HAART-treated patients between 2003 and 2009 in Rwanda. International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies 8-12 June, 2010 Dubrovnik, Croatia Antiretroviral Therapy. p. A143.
van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte EF, Reid T. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 2010; 104(2): 148-153.
Fabbiani M, Di Giambenedetto S, Bracciale L, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 2009; 64(1): 109-117.
Clevenbergh P, Mouly S, Sellier P, et al. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view. Curr HIV Res 2004; 2(4): 309-321.
de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54(4): 378-385.
Macnab KA, Gill MJ, Sutherland LR, De Boer Visser N, Church D. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother. 1993; 31(3): 421-428.
Ivanovic J, Nicastri E, Ascenzi P, et al. Therapeutic drug monitoring in the management of HIV-infected patients. Curr Med Chem 2008; 15(19): 1925-1939.
Shannon IL, Suddick RP, Dowd FJ, Jr. Saliva: composition and secretion. Monogr Oral Sci 1974; 2: 1-103.
Grossman L, Brickman B. Some Observations on the pH of Saliva. J Dent Res 1937; 16: 409-416.
Almond LM, Boffito M, Hoggard PG, et al. Nevirapine Protein Binding in HIV Infected Individuals. 6th International Congress on Drug Therapy in HIV Infection 17-21 November 2002 Glasgow, UK Int Cong Drug Therapy HIV 2002 Nov 17-21. p. Abstract No. P164.
Rolinski B, Wintergerst U, Goebel FD, Roscher AA, Belohradsky BH. Determination of the protein-bound fraction of zidovudine in serum. 7th International AIDS Conference June 16-21, 1991 Florence, Italy. p. 208. Abstract #W.B.2107.
Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36(1): 41-66.
Rasmussen F. Salivary Excretion of Sulphonamides and Barbiturates by Cows and Goats. Acta Pharmacol Toxicol (Copenh) 1964; 21: 11-19.